PF-08634404 with Chemotherapy for Metastatic Colorectal Cancer

This study aims to evaluate a new medication called PF-08634404 in people with advanced colorectal cancer, which is cancer of the colon or rectum that has spread to other parts of the body. The study will compare the effectiveness and safety of PF-08634404 combined with standard chemotherapy against another treatment option, Bevacizumab combined with chemotherapy. The participants will be individuals who are at least 18 years old, have metastatic colorectal cancer, and are healthy enough to undergo the treatment. This research is important as it seeks to find a potentially more effective treatment option for patients whose cancer has progressed despite previous treatments. Participants will be randomly assigned to receive either PF-08634404 with chemotherapy or Bevacizumab with chemotherapy. Neither the participants nor the doctors will know which treatment is being administered to maintain objectivity. All medications will be given through IV infusions at a clinical site, where medical staff will carefully monitor participants. Treatments will be given in cycles, and participants will continue as long as they benefit and tolerate the treatment well. The study will last up to 33 months per participant, with regular health checks and tests at the study site. After the treatment ends, there will be a follow-up visit 30 to 37 days later, and ongoing follow-ups every 12 weeks to monitor health and any new treatments.